ZimVie Inc (ZIMV) Gets a Sell From Barclays
Needham Maintains ZimVie(ZIMV.US) With Buy Rating, Maintains Target Price $23
ZimVie Analyst Ratings
Needham Maintains ZimVie(ZIMV.US) With Buy Rating, Raises Target Price to $23
Buy Rating Affirmed for ZimVie Inc. Amid Market Challenges and Positive Growth Indicators
ZimVie Analyst Ratings
ZimVie Analyst Ratings
Barclays Sticks to Their Sell Rating for ZimVie Inc (ZIMV)
Needham: Reiterates that ZimVie (ZIMV.US) holds the rating.
ZimVie Analyst Ratings
Needham Sticks to Their Hold Rating for ZimVie Inc (ZIMV)
Needham: Reiterates that ZimVie (ZIMV.US) holds the rating.
ZimVie Analyst Ratings
Analysts Have Conflicting Sentiments on These Healthcare Companies: ZimVie Inc (ZIMV) and Merus (MRUS)
ZimVie Analyst Ratings
Barclays Maintains Underweight on ZimVie, Raises Price Target to $16
Analysts Offer Insights on Healthcare Companies: Ginkgo Bioworks Holdings (DNA), ZimVie Inc (ZIMV) and Veeva Systems (VEEV)
Needham Sticks to Its Hold Rating for ZimVie Inc (ZIMV)
ZimVie Inc (ZIMV) Gets a Hold From Needham
ZimVie Analyst Ratings